Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: neostigmine Clear all
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

NCT03351608
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 25, 2026, 5:48 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease

NCT07203287
View directory record Official record
Conditions
Post Operative Pulmonary Complications, Neuromuscular Blockade, General Anesthesia
Interventions
Rocuronium, Cisatracurium, Sugammadex, Neostigmine
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 80 Years
Enrollment
490 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 25, 2026, 5:48 PM EDT
Recruiting Phase 3 Interventional

Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial

NCT06136585
View directory record Official record
Conditions
Neuromuscular Blocks
Interventions
2 mg/kg sugammadex, 0.07 mg/kg neostigmine
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 25, 2026, 5:48 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Residual Neuromuscular Blockade in Cardiac Surgery Patients

NCT03574337
View directory record Official record
Conditions
Residual Neuromuscular Blockade
Interventions
Sugammadex, neostigmine/glycopyrolate
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Sep 25, 2026, 5:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Transdermal Iontophoresis of Vitamin B12 Under Three Different Skin Preparations

NCT04027959
View directory record Official record
Conditions
Macrocytic Anemia With Vitamin B12 Deficiency
Interventions
Vitamin B12
Dietary Supplement
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Sep 25, 2026, 5:48 PM EDT
Completed No phase listed Observational

Reversal of Neuromuscular Blockade in Thoracic Surgical Patients

NCT01837498
View directory record Official record
Conditions
Residual Neuromuscular Blockade
Interventions
Neostigmine, Sugammadex
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Sep 25, 2026, 5:48 PM EDT
Completed Phase 4 Interventional Results available

Neuromuscular Blockade on Shoulder Pain of Elderly

NCT03210376
View directory record Official record
Conditions
Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Urinary Tract
Interventions
Deep Neuromuscular Blockade (NMB), Moderate Neuromuscular Blockade (NMB), Sugammadex, Neostigmine, Pain Assessment
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 25, 2026, 5:48 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Use of High Resolution Colonic Manometry in Studying Motility

NCT02574611
View directory record Official record
Conditions
Gastrointestinal Dysfunction
Interventions
Neostigmine, Glycopyrrolate, Saline (Placebo), High Resolution Colonic Manometry
Drug · Other · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 25, 2026, 5:48 PM EDT
Not listed Phase 1 Interventional

Use of Prokinetics During Inpatient Bowel Care for SCI Patients

NCT02370433
View directory record Official record
Conditions
Spinal Cord Injury, Neurogenic Bowel
Interventions
Intravenous Neostigmine and Glycopyrrolate, Transdermal Neostigmine and Glycopyrrolate
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 25, 2026, 5:48 PM EDT
Not listed Phase 4 Interventional

Neostigmine Route for Acute Colonic Pseudo Obstruction

NCT04951726
View directory record Official record
Conditions
Ogilvie Syndrome
Interventions
Neostigmine
Drug
Lead sponsor
University of Southern California
Other
Eligibility
16 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 25, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant

NCT03116997
View directory record Official record
Conditions
Surgery
Interventions
Neostigmine+glycopyrrolate, Sugammadex
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 25, 2026, 5:48 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Phase I Clinical Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of CW002

NCT01338935
View directory record Official record
Conditions
Healthy
Interventions
CW 002
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 49 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Sep 25, 2026, 5:48 PM EDT
Terminated Phase 4 Interventional Results available

Avoiding Neuromuscular Blockers to Reduce Complications

NCT03962725
View directory record Official record
Conditions
Respiratory Failure, Respiratory Infection, Aspiration Pneumonia, Pneumonitis, Atelectasis, Bronchospasm
Interventions
Neuromuscular Blocking Agents, Anesthetic Adjuncts
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 25, 2026, 5:48 PM EDT
Completed Not applicable Interventional

Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?

NCT02037516
View directory record Official record
Conditions
Respiratory Complication, Morbid Obesity
Interventions
Accelomyography, Neostigmine, Qualitative Monitor
Device · Drug
Lead sponsor
Coastal Anesthesiology Consultants
Other
Eligibility
Not listed
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Saint Augustine, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 25, 2026, 5:48 PM EDT
Recruiting Phase 2 Interventional

Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture

NCT05116930
View directory record Official record
Conditions
Post-Dural Puncture Headache
Interventions
Neostigmine, Glycopyrrolate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 25, 2026, 5:48 PM EDT
Completed Phase 4 Interventional Results available

Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery

NCT03939923
View directory record Official record
Conditions
Surgery, Coronary Artery Disease
Interventions
Rocuronium, Neostigmine, Glycopyrrolate, Sugammadex
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 25, 2026, 5:48 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex as Rescue Therapy

NCT05661409
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 25, 2026, 5:48 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

NMBA Reversal and Postoperative Urinary Retention

NCT06948409
View directory record Official record
Conditions
Neuromuscular Blocking Agents, Urinary Retention After Procedure, Urinary Retention Postoperative, Neuromuscular Blockade Reversal Agent, Neuromuscular Blockade, Costs, Atropine, Sugammadex, Glycopyrrolate, Neostigmine, Anesthesia
Interventions
Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
70,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 25, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Intranasal Administration of a Prokinetic for Bowel Evacuation in Persons With SCI

NCT00855283
View directory record Official record
Conditions
SCI
Interventions
IN NEO, IN NEO + IN Glycopyrrolate, IV Visit
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Sep 25, 2026, 5:48 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular

NCT03322657
View directory record Official record
Conditions
Neuromuscular Blockade, Anesthesia
Interventions
Neostigmine, Glycopyrrolate, Sugammadex
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Sep 25, 2026, 5:48 PM EDT
Completed Phase 4 Interventional Results available

Best Management of Muscle Relaxation- Objective Monitoring

NCT03958201
View directory record Official record
Conditions
Residual Paralysis, Post Anesthesia
Interventions
Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex
Combination Product
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 25, 2026, 5:48 PM EDT
Completed Not applicable Interventional Results available

The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers

NCT00633256
View directory record Official record
Conditions
Smoking
Interventions
Cycloserine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Sep 25, 2026, 5:48 PM EDT
Completed Phase 4 Interventional Results available

Investigation of Sugammadex in Outpatient Urological Procedures

NCT03138967
View directory record Official record
Conditions
Malignant Neoplasms of Urinary Tract, Bladder Cancer
Interventions
Rocuronium, Sugammadex, Neostigmine, Glycopyrrolate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 25, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Results available

Epidural Neostigmine for Labor Pain

NCT00779467
View directory record Official record
Conditions
Labor Pain
Interventions
Neostigmine, Bupivacaine, fentanyl
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 25, 2026, 5:48 PM EDT